Logo image of AYLA

AYALA PHARMACEUTICALS INC (AYLA) Stock Fundamental Analysis

USA - NASDAQ:AYLA - US05465V1089 - Common Stock

0.5036 USD
+0.03 (+5.84%)
Last: 1/18/2023, 8:00:01 PM
Fundamental Rating

2

Overall AYLA gets a fundamental rating of 2 out of 10. We evaluated AYLA against 534 industry peers in the Biotechnology industry. AYLA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AYLA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AYLA has reported negative net income.
In the past year AYLA has reported a negative cash flow from operations.
AYLA Yearly Net Income VS EBIT VS OCF VS FCFAYLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 -10M -20M -30M -40M

1.2 Ratios

AYLA has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AYLA Yearly ROA, ROE, ROICAYLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 -20 -40 -60 -80 -100

1.3 Margins

The Gross Margin of AYLA (5.19%) is better than 74.49% of its industry peers.
The Profit Margin and Operating Margin are not available for AYLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 5.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AYLA Yearly Profit, Operating, Gross MarginsAYLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 0 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

AYLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AYLA has more shares outstanding
AYLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AYLA Yearly Shares OutstandingAYLA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2M 4M 6M 8M 10M
AYLA Yearly Total Debt VS Total AssetsAYLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 10M 20M 30M 40M

2.2 Solvency

AYLA has an Altman-Z score of -20.92. This is a bad value and indicates that AYLA is not financially healthy and even has some risk of bankruptcy.
AYLA's Altman-Z score of -20.92 is on the low side compared to the rest of the industry. AYLA is outperformed by 90.14% of its industry peers.
AYLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.92
ROIC/WACCN/A
WACC8.99%
AYLA Yearly LT Debt VS Equity VS FCFAYLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 0 20M -20M

2.3 Liquidity

A Current Ratio of 2.28 indicates that AYLA has no problem at all paying its short term obligations.
AYLA has a worse Current ratio (2.28) than 79.97% of its industry peers.
AYLA has a Quick Ratio of 2.28. This indicates that AYLA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.28, AYLA is doing worse than 77.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.28
AYLA Yearly Current Assets VS Current LiabilitesAYLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 10M 20M 30M 40M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.10% over the past year.
AYLA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -48.36%.
EPS 1Y (TTM)13.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.94%
Revenue 1Y (TTM)-48.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-85.44%

3.2 Future

Based on estimates for the next years, AYLA will show a decrease in Earnings Per Share. The EPS will decrease by -8.08% on average per year.
Based on estimates for the next years, AYLA will show a very negative growth in Revenue. The Revenue will decrease by -12.82% on average per year.
EPS Next Y3.59%
EPS Next 2Y8.3%
EPS Next 3Y-8.08%
EPS Next 5YN/A
Revenue Next Year-33.92%
Revenue Next 2Y-12.82%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

AYLA Yearly Revenue VS EstimatesAYLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 1M 2M 3M
AYLA Yearly EPS VS EstimatesAYLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AYLA. In the last year negative earnings were reported.
Also next year AYLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AYLA Price Earnings VS Forward Price EarningsAYLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AYLA Per share dataAYLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

A cheap valuation may be justified as AYLA's earnings are expected to decrease with -8.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.3%
EPS Next 3Y-8.08%

More info and screens

0

5. Dividend

5.1 Amount

AYLA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AYALA PHARMACEUTICALS INC

NASDAQ:AYLA (1/18/2023, 8:00:01 PM)

0.5036

+0.03 (+5.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2022-11-03/amc
Earnings (Next)03-27 2023-03-27
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners22.37%
Ins Owner Change0%
Market Cap7.46M
Revenue(TTM)1.73M
Net Income(TTM)-38474000
Analysts77.78
Price Target12.24 (2330.5%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.08%
Min EPS beat(2)-30.98%
Max EPS beat(2)18.82%
EPS beat(4)2
Avg EPS beat(4)-3.67%
Min EPS beat(4)-30.98%
Max EPS beat(4)18.82%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-89.78%
Min Revenue beat(2)-93.96%
Max Revenue beat(2)-85.61%
Revenue beat(4)1
Avg Revenue beat(4)-40.87%
Min Revenue beat(4)-93.96%
Max Revenue beat(4)61.99%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.86%
PT rev (3m)6.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-43.61%
EPS NY rev (1m)0%
EPS NY rev (3m)-22.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-42.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)15.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.31
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)-2.52
EYN/A
EPS(NY)-2.34
Fwd EYN/A
FCF(TTM)-2.3
FCFYN/A
OCF(TTM)-2.3
OCFYN/A
SpS0.12
BVpS0.55
TBVpS0.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 5.19%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.28
Quick Ratio 2.28
Altman-Z -20.92
F-Score4
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)305.81%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.94%
EPS Next Y3.59%
EPS Next 2Y8.3%
EPS Next 3Y-8.08%
EPS Next 5YN/A
Revenue 1Y (TTM)-48.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-85.44%
Revenue Next Year-33.92%
Revenue Next 2Y-12.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-39.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-39.27%
OCF growth 3YN/A
OCF growth 5YN/A

AYALA PHARMACEUTICALS INC / AYLA FAQ

Can you provide the ChartMill fundamental rating for AYALA PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 2 / 10 to AYLA.


Can you provide the valuation status for AYALA PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 2 / 10 to AYALA PHARMACEUTICALS INC (AYLA). This can be considered as Overvalued.


Can you provide the profitability details for AYALA PHARMACEUTICALS INC?

AYALA PHARMACEUTICALS INC (AYLA) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for AYLA stock?

The Earnings per Share (EPS) of AYALA PHARMACEUTICALS INC (AYLA) is expected to grow by 3.59% in the next year.